学术探索
学术期刊
新闻热点
数据分析
智能评审

Unraveling severe sepsis - Why did OPTIMIST fail and what's next?

被引：27
作者：
Angus, DC
Crowther, MA
机构：
[1] Univ Pittsburgh, Dept Crit Care Med, Clin Res Invest & Syst Modeling Acute Illness Lab, Pittsburgh, PA 15261 USA
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 290卷 / 02期
关键词：
D O I：
10.1001/jama.290.2.256
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：256 / 258
页数：3
相关论文
共 35 条
  • [1] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial
    Abraham, E
    Reinhart, K
    Opal, S
    Demeyer, I
    Doig, C
    Rodriguez, AL
    Beale, R
    Svoboda, P
    Laterre, PF
    Simon, S
    Light, B
    Spapen, H
    Stone, J
    Seibert, A
    Peckelsen, C
    De Deyne, C
    Postier, R
    Pettilä, V
    Sprung, CL
    Artigas, A
    Percell, SR
    Shu, V
    Zwingelstein, C
    Tobias, J
    Poole, L
    Stolzenbach, JC
    Creasey, AA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02): : 238 - 247
  • [2] Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis - Question and answer session after scientific review
    Vincent, JL
    Abraham, E
    Esmon, C
    Hack, CE
    [J]. CRITICAL CARE MEDICINE, 2000, 28 (09) : S33 - S33
  • [3] The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome
    Aird, WC
    [J]. BLOOD, 2003, 101 (10) : 3765 - 3777
  • [4] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [5] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, G
    van Hout, B
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (01) : 1 - 11
  • [6] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    Annane, D
    Sébille, V
    Charpentier, C
    Bollaert, PE
    François, B
    Korach, JM
    Capellier, G
    Cohen, Y
    Azoulay, E
    Troché, G
    Chaumet-Riffaut, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07): : 862 - 871
  • [7] Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study
    Baudo, F
    Caimi, TM
    de Cataldo, F
    Ravizza, A
    Arlati, S
    Casella, G
    Carugo, D
    Palareti, G
    Legnani, C
    Ridolfi, L
    Rossi, R
    D'Angelo, A
    Crippa, L
    Giudici, D
    Gallioli, G
    Wolfler, A
    Calori, G
    [J]. INTENSIVE CARE MEDICINE, 1998, 24 (04) : 336 - 342
  • [8] Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis
    Bernard, GR
    Ely, EW
    Wright, TJ
    Fraiz, J
    Stasek, JE
    Russell, JA
    Mayers, I
    Rosenfeld, BA
    Morris, PE
    Yan, SB
    Helterbrand, JD
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (11) : 2051 - 2059
  • [9] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [10] Why sepsis trials fail
    Bone, RC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (07): : 565 - 566
1234